Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer

New England Journal of Medicine

Volumn 378, Issue 22, 2018, Pages 2078-2092

  Gandhi, L ^a   Rodriguez Abreu D ^b   Gadgeel, S ^g   Esteban, E ^c   Felip, E ^d   De Angelis, F ^h   Domine, M ^e   Clingan, P ^j   Hochmair, M J ⁿ   Powell, S F ^o   Cheng, S Y S ⁱ   Bischoff, H G ^p   Peled, N ^r   Grossi, F ^s   Jennens, R R ^k   Reck, M ^q   Hui, R ^l   Garon, E B ^v   Boyer, M ^m   Rubio Viqueira, B ^f   Novello, S ^t   Kurata, T ^w   Gray, J E ^x   Vida, J ^y   Wei, Z ^y   Yang, J ^y   Raftopoulos, H ^y   Pietanza, M C ^y   Garassino, M C ^u   more..

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^f Hospital Universitario Quiron Madrid   (Spain)

^g KARMANOS CANCER INSTITUTE   (United States)

^h Integrated Health and Social Services Centres   (Canada)

ⁱ SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^j Southern Medical Day Care Centre   (Australia)

^k EPWORTH HEALTHCARE   (Australia)

^l UNIVERSITY OF SYDNEY   (Australia)

^m Chris O Brien Lifehouse   (Australia)

ⁿ OTTO WAGNER HOSPITAL   (Austria)

^o SANFORD RESEARCH   (United States)

^p Thoraxklinik   (Germany)

^q GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^r TEL AVIV UNIVERSITY   (Israel)

^s UNIVERSITY OF GENOA   (Italy)

^t SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^u NATIONAL CANCER INSTITUTE   (Italy)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^x H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^y MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLIC ACID; GLUCOCORTICOID; PEMBROLIZUMAB; PEMETREXED; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADULT; AGED; ANEMIA; ARTERY EMBOLISM; ARTICLE; ASTHENIA; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CANCER GROWTH; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GENE MUTATION; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEMOPTYSIS; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOKALEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INFUSION RELATED REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE ISCHEMIA; KIDNEY FAILURE; LACRIMATION DISORDER; LUNG INFECTION; LUNG INSUFFICIENCY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC NON SMALL CELL LUNG CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYOSITIS; NAUSEA; NEPHRITIS; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL EDEMA; PERITONITIS; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SKIN DISEASE; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 85047328215     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1801005     Document Type: Article

References (31)

1. Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D, McCusker ME. Realworld treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies. PLoS One 2017; 12(4): E0175679.
2. Lazzari C, Bulotta A, Ducceschi M, et al. Historical evolution of second-line therapy in non-small cell lung cancer. Front Med (Lausanne) 2017; 4: 4.
3. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: Implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014; 21: 15-25.
4. Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid- derived suppressor cells. Oncoimmunology 2017; 6(7): E1331807.
5. Roselli M, Cereda V, di Bari MG, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2013; 2(10): E27025.
6. Lesterhuis WJ, Punt CJ, Hato SV, et al. Platinum-based drugs disrupt STAT6- mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011; 121: 3100-8.
7. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016; 17: 1497-508.
8. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
9. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
10. Ahn MJ, Gandhi L, Hamid O, et al. Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2015; 26: Suppl 9: 459P.
11. Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 2016; 24: 392-7.
12. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-smallcell lung cancer. N Engl J Med 2016; 375: 1823-33.
13. Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. Progression after the next line of therapy (PFS2) and updated OS among patients with advanced NSCLC and PD-L1 TPS =50% enrolled in KEYNOTE-024. J Clin Oncol 2017; 35: Suppl: 9000. abstract.
14. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non- small-cell lung cancer. N Engl J Med 2015; 372: 2018-28.
15. Reck M, Socinski MA, Cappuzzo F, et al. Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMPower150). Ann Oncol 2017; 28: Suppl 11:LBA1.
16. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39.
17. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35.
18. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017; 376: 2415-26.
19. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated nonsmall- cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389: 255-65.
20. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE- 010): A randomised controlled trial. Lancet 2016; 387: 1540-50.
21. Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017; 35: 2781-9.
22. Cutica I, Vie GM, Pravettoni G. Personalised medicine: The cognitive side of patients. Eur J Intern Med 2014; 25: 685-8.
23. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-40.
24. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31: 2895-902.
25. Scagliotti GV, Gridelli C, de Marinis F, et al. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. Lung Cancer 2014; 85: 408-14.
26. Tomasini P, Barlesi F, Mascaux C, Greillier L. Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: Latest evidence about its extended use and outcomes. Ther Adv Med Oncol 2016; 8: 198-208.
27. Perol M, Audigier-Valette C, Molinier O, et al. IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous NSCLC. J Clin Oncol 2017; 35: 15 Suppl:9003.
28. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: Randomized, openlabel, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-smallcell lung cancer. J Thorac Oncol 2015; 10: 134-42.
29. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-smallcell lung cancer (PARAMOUNT): A doubleblind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-55.
30. Zattera T, Londrino F, Trezzi M, et al. Pemetrexed-induced acute kidney failure following irreversible renal damage: Two case reports and literature review. J Nephropathol 2017; 6: 43-8.
31. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003; 4: 889-901.